Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.
Metformin combination products
Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
Effect of DapagliFLOzin on Quality of Life in Patients With Type 2 Diabetes in a Real Clinical PrActice
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2016-05-20
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT02719132
Pharmacokinetic-Pharmacodynamic Relationship of Metformin in Healthy Volunteers
- First Posted Date
- 2016-03-18
- Last Posted Date
- 2016-03-18
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT02712619
May Metformin be Used in Renal Failure?
- Conditions
- Renal Disorder Associated With Type II Diabetes Mellitus
- Interventions
- First Posted Date
- 2016-03-16
- Last Posted Date
- 2016-04-26
- Lead Sponsor
- Centre Hospitalier Universitaire, Amiens
- Target Recruit Count
- 82
- Registration Number
- NCT02710448
- Locations
- 🇫🇷
Service d'Endocrinologie, Maladies Métaboliques et Nutrition, Amiens, France
SGLT2 Inhibitors and Metformin on Metabolism and Non-Alcoholic SteatoHepatitis
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- Drug: SGLT2 inhibitorDrug: Metformin
- First Posted Date
- 2016-03-02
- Last Posted Date
- 2018-05-04
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 20
- Registration Number
- NCT02696941
- Locations
- 🇬🇧
University of Oxford, Oxford, United Kingdom
The PRE-D Trial: Effect of Dapagliflozin, Metformin and Physical Activity in Pre-diabetes
- Conditions
- Prediabetic StateObesity
- Interventions
- First Posted Date
- 2016-03-01
- Last Posted Date
- 2019-10-07
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Target Recruit Count
- 120
- Registration Number
- NCT02695810
- Locations
- 🇩🇰
Steno Diabetes Center A/S, Gentofte, Denmark
Effects of Metformin in Heart Failure Patients
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Subcutaneous (sliding scale) InsulinDrug: Metformin
- First Posted Date
- 2016-02-29
- Last Posted Date
- 2018-11-23
- Lead Sponsor
- Maya Guglin
- Registration Number
- NCT02694289
Effects of Cyproterone Compound-spironolactone, Metformin and Pioglitazone on Inflammatory Markers in PCOS
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Shiraz University of Medical Sciences
- Target Recruit Count
- 90
- Registration Number
- NCT02689843
- Locations
- 🇮🇷
Shahid Motahhari Clinic, Shiraz University of Medical Sciences, Shiraz, Fars, Iran, Islamic Republic of
Effect of GLP-1 on Angiogenesis
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2016-02-19
- Last Posted Date
- 2021-06-15
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 50
- Registration Number
- NCT02686177
- Locations
- 🇫🇷
Nutrition department, pole ENDO - Assistance Publique Hôpitaux Marseille, Marseille, France
Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD
- Conditions
- Age-Related Macular DegenerationDry Macular DegenerationGeographic AtrophyMacular Degeneration, Age-Related
- Interventions
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 66
- Registration Number
- NCT02684578
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸University of California, Davis, Davis, California, United States
🇺🇸Palo Alto Veteran Affairs Medical Center, Palo Alto, California, United States
Mitochondrial-related Platelet Transcript Expression Levels in Pre-diabetic Subjects Randomized to Metformin or Placebo
- First Posted Date
- 2016-02-15
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 55
- Registration Number
- NCT02682121
- Locations
- 🇺🇸
University of Utah, Salt Lake City, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.